Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 5905-5915

  Ong, Yong Sze ^a   Saiful Yazan, Latifah ^a   Ng, Wei Keat ^a   Noordin, Mustapha M ^a   Sapuan, Sarah ^a   Foo, Jhi Biau ^a   Tor, Yin Sim ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Nanostructured lipid carrier; Thymoquinone; Toxicity

Indexed keywords

NANOCARRIER; THYMOQUINONE; BENZOQUINONE DERIVATIVE; LIPID; NANOMATERIAL;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOCHEMICAL ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; FEMALE; GENDER; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; IN VIVO STUDY; LIVER FUNCTION; LIVER TOXICITY; LONG TERM EXPOSURE; MALE; MORTALITY; MOUSE; NANOENCAPSULATION; NONHUMAN; ORGAN WEIGHT; SURVIVAL; ANIMAL; BLACK CUMIN; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; HUMAN; LIVER; PLANT SEED; TOXICITY TESTING; TUMOR CELL LINE;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMPOUNDING; FEMALE; HUMANS; LIPIDS; LIVER; MALE; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; NIGELLA SATIVA; SEEDS; TOXICITY TESTS, ACUTE;

EID: 84995554287     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S114205     Document Type: Article

References (40)

1. Gali-Muhtasib H, Roessner A, Schneider-Stock R. Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol. 2006;38(8):1249–1253.
2. Khader M, Bresgen N, Eckl PM. In vitro toxicological properties of thymoquinone. Food Chem Toxicol. 2009;47(1):129–133.
3. Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother Res. 2004; 18(3):195–199.
4. Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res. 2000;14(5):323–328.
5. Gali-Muhtasib H, Ocker M, Kuester D, et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med. 2008;12(1):330–342.
6. Ali Salim LZ, Othman R, Abdulla MA, et al. Thymoquinone inhibits murine leukemia WEHI-3 cells in vivo and in vitro. PLoS One. 2014; 9(12):e115340.
7. Jrah Harzallah H, Grayaa R, Kharoubi W, Maaloul A, Hammami M, Mahjoub T. Thymoquinone, the Nigella sativa bioactive compound, prevents circulatory oxidative stress caused by 1,2-dimethylhydrazine in erythrocyte during colon postinitiation carcinogenesis. Oxid Med Cell Longev. 2012;2012:6.
8. Ng WK, Saiful Yazan L, Yap LH, Wan Nor Hafiza WA, How CW, Abdullah R. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). Biomed Res Int. 2015;2015:10.
9. Schneider-Stock R, Fakhoury IH, Zaki AM, El-Baba CO, Gali-Muhtasib HU. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19(1):18–30.
10. Pathan SA, Jain GK, Zaidi SMA, et al. Stability-indicating ultraperformance liquid chromatography method for the estimation of thymoquinone and its application in biopharmaceutical studies. Biomed Chromatogr. 2011;25(5):613–620.
11. Gabizon A, Bradbury M, Prabhakar U, Zamboni W, Libutti S, Grodzinski P. Cancer nanomedicines: closing the translational gap. Lancet. 2014;384(9961):2175–2176.
12. Yu D-G, Li X-Y, Wang X, Yang J-H, Bligh SWA, Williams GR. Nanofibers fabricated using triaxial electrospinning as zero order drug delivery systems. ACS Appl Mater Interfaces. 2015;7(33):18891–18897.
13. Hierrezuelo J, Peláez L, Benavente J, Manuel Juan L-R, Rico R, Armengol R. Bioengineered nanomaterials. In: Tiwari A, editor. Lipid Cyclodext Nanocarriers Loadind Bioact Agents Stab Polym Support. Florida: CRC Press; 2013:226.
14. Dehghani H, Hashemi M, Entezari M, Mohsenifar A. The comparison of anticancer activity of thymoquinone and nanothymoquinone on human breast adenocarcinoma. Iran J Pharm Res. 2015;14(2): 539–546.
15. Yu D-G, Zhu L-M, Branford-White CJ, et al. Solid dispersions in the form of electrospun core-sheath nanofibers. Int J Nanomedicine. 2011;6:3271–3280.
16. Rodrigues BVM, Leite NCS, Cavalcanti B, et al. Graphene oxide/ multi-walled carbon nanotubes as nanofeatured scaffolds for the assisted deposition of nanohydroxyapatite: characterization and biological evaluation. Int J Nanomedicine. 2016;11:2569–2585.
17. Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi. 2008;128(2): 269–280.
18. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2): 97–109.
19. Lin X, Li X, Zheng L, Yu L, Zhang Q, Liu W. Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp. 2007;311(1–3):106–111.
20. Zhang XY, Qiao H, Ni JM, Shi YB, Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur J Pharm Sci. 2013;49(3): 411–422.
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284.
22. Buxton DB, Lee SC, Wickline SA, Ferrari M; National Heart, Lung, and Blood Institute Nanotechnology Working Group. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation. 2003;108(22):2737–2742.
23. European Technology Platform on Nanomedicine. Vision Paper and Basis for a Strategic Research Agenda for Nanomedicine. Luxembourg: Official Publications of the European Commission; 2005:37.
24. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171.
25. Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM. Toxicology and clinical potential of nanoparticles. Nano Today. 2011;6(6):585–607.
26. Varshosaz J, Hassanzadeh F, Sadeghi H, Andalib S. Synthesis of octadecylamine-retinoic acid conjugate for enhanced cytotoxic effects of 5-FU using LDL targeted nanostructured lipid carriers. Eur J Med Chem. 2012;54:429–438.
27. European Union Executive. Commission recommendation of 18 October 2011 on the definition of nanomaterial. Off J Eur Union. 2011;L275:1.
28. Paini M, Daly SR, Aliakbarian B, et al. An efficient liposome based method for antioxidants encapsulation. Colloids Surf B Biointerfaces. 2015;136:1067–1072.
29. Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru. 2011;19(1): 23–32.
30. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(suppl 1):S131–S155.
31. Montaner J, Cano-Sarabia M, Simats A, et al. Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int J Nanomedicine. 2016;11:3035–3048.
32. El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol. 2009;2009:754810.
33. OECD. Test No. 420: Acute Oral Toxicity – Fixed Dose Procedure. OECD Publishing; 2001. Available from: https://ntp.niehs.nih.gov/ iccvam/suppdocs/feddocs/oecd/oecd_gl420.pdf. Accessed June 3, 2016.
34. Wang X, Su S, Ihsan A, et al. Acute and sub-chronic toxicity study of diaveridine in wistar rats. Regul Toxicol Pharmacol. 2015;73(1):232–240.
35. OECD. Test No. 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents. OECD Publishing; 2008. Available from: http://www.oecd. org/env/test-no-407-repeated-dose-28-day-oral-toxicity-study-in-rodents-9789264070684-en.htm. Accessed June 3, 2016.
36. Teo S, Stirling D, Thomas S, Hoberman A, Kiorpes A, Khetani V. A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in Sprague–Dawley rats. Toxicology. 2002;179(3): 183–196.
37. Hu X, Cheng S, Liu X, et al. Development of monoclonal antibodies and immunochromatographic lateral flow device for rapid test of alanine aminotransferase isoenzyme 1. Protein Expr Purif. 2016;119: 94–101.
38. Wang H, Sit W-H, Tipoe GL, Wan JM-F. Differential protective effects of extra virgin olive oil and corn oil in liver injury: a proteomic study. Food Chem Toxicol. 2014;74:131–138.
39. Meerts IATM, Verspeek-Rip CM, Buskens CAF, et al. Toxicological evaluation of pomegranate seed oil. Food Chem Toxicol. 2009;47(6): 1085–1092.
40. Center for Drug Evaluation and Research. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Dep Heal Hum Serv; 2005:1–27.